ClinicalTrials.gg
CompletedNCT04486950Updated Mar 10, 2023Results posted

A Study of TAK-951 in Healthy Adults

A Phase 1 interventional study of TAK-951 and TAK-951 Placebo in Healthy Volunteer, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-10.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

It is hoped that a medicine called TAK-951 will eventually be used to treat nausea and vomiting. Before then, the sponsor needs to understand how the body processes TAK-951 in healthy adults.

The main aims of this study are as follows:

  • To check for side effects from TAK-951 when given at a slow and fast infusion rate.
  • To learn how much TAK-951 participants can receive without getting side effects from it.

Participants will receive a single infusion of either TAK-951 or placebo. In this study, a placebo looks like TAK-951 but does not have any medicine in it. Participants will receive either a low dose or high dose of TAK-951. The infusion will take from 1-3 hours.

Participants will stay in the study clinic for about 4 days to receive the study medicine (TAK-951 or placebo) and check for side effects. They will have follow-up visits at the clinic about 2 weeks and 4 weeks after treatment.

Read the detailed description

The drug being tested in this study is called TAK-951. The study will evaluate the safety, tolerability and PK of TAK-951 in healthy participants.

The study will enroll approximately 40 healthy participants. Each cohort will have 8 participants to be randomized and a minimum of 3 cohorts will be evaluated. Participants will be randomly assigned (by chance, like flipping a coin) to receive TAK-951 or placebo in a 6:2 ratio in one of the following 3 cohorts, which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Cohort 1 (Low Dose): TAK-951 20 mcg Infusion Over 60 Minutes
  • Cohort 2 (High Dose): TAK-951 1 mg Infusion Over 60 Minutes
  • Cohort 3: TAK-951 1 mg Infusion over 120 Minutes

Sentinel dosing will be done in first 2 participants in each cohort. The dosing in rest of the cohort will done if there are no significant safety or tolerability concerns. Additional 2 cohorts, each cohort with 8 participants may be added in study to evaluate additional intravenous dosing regimen after clinical data analysis of first 3 cohorts. Dosing of the subsequent cohort will be based on the analysis of the previous cohort's data.

This single-center trial will be conducted in the United States. The overall time to participate in this study is up to 57 days. All participants will return to clinic after 14 and 28 days after the last visit to the clinic for a follow-up assessment.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Continuous non-smoker who has not used nicotine- and tobacco-containing products and/or cannabis products for at least 3 months prior to dosing and throughout the study.
  2. (BMI) greater than or equal to (>=) 18.0 and less than or equal to (\<=) 32.0 kilogram per square meter (kg/m\^2) at screening.
  3. Female must be of non-.

Exclusion criteria

Exclusion Criteria:

  1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. Drink alcohol in excess of 21 glasses/units per week for males or 14 glasses/units per week for females, with one unit equal to (=) 150 milliliter (mL) of wine or 360 mL of beer or 45 mL of 45 percent (%) alcohol.
  3. Have any tattoos, scars or skin issue at planned IV infusion site which could interfere with dosing.
  4. History or presence of:

    • Three (3) or more incidences of vasovagal syncope within the last 5 years prior to screening.
    • Family history of unexplained sudden death or channelopathy.
    • Brugada syndrome (that is, right bundle branch block (RBBB) pattern with ST-elevation in leads V1-V3).
    • Cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction, stroke, sick sinus syndrome, pulmonary congestion, symptomatic or significant cardiac arrhythmia, second-degree AV block type 2, third-degree AV block, prolonged interval by Fredericia (QTcF) interval, hypokalemia, hypomagnesemia, or conduction abnormalities;
    • Risk factors for Torsade de Pointes (example, heart failure, cardiomyopathy, or family history of Long QT Syndrome);
    • Any findings or medical history including: long or short QT interval with QTcF (over 450 msec or less than 360 msec), bifascicular block or QRS >=120 msec or PR interval greater than (>) 200 msec at screening or Day -1 pre-Hour 0.
    • Documented history of sinoatrial block or sinus pause >=3 seconds.
  5. Semi-recumbent blood pressure (average of duplicate) is less than 90/60 millimeter of mercury (mmHg) or greater than 140/90 mmHg at screening.
  6. Has an average semi-recumbent heart rate \<60 or >100 beats per minute (bpm) (at screening, at Day -1 pre-Hour 0, or at pre-dose Day 1); athletic participants with an average semi-recumbent heart rate \<60 bpm can be enrolled only with medical monitor approval. If participant has heart rate \<60 bpm Investigator should obtain medical approval from Sponsor.
  7. Has orthostatic hypotension defined as a decrease in systolic blood pressure >=20 mmHg or a decrease in diastolic blood pressure >=10 mmHg after 2 minutes of standing when compared with blood pressure from the semi-recumbent position at screening and at Day -1 pre-Hour 0. The semi-recumbent blood pressure will be an average of duplicate measurements.
  8. Has postural orthostatic tachycardia, defined as an increase of 30 bpm or heart rate >120 bpm after standing for 2 minutes.
  9. Positive urine drug or alcohol results at screening or check-in.
  10. Positive urine cotinine at screening or check-in.
  11. Positive results at screening for (HIV), surface antigen (HBsAg), or virus (HCV).
  12. Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to dosing and throughout the study. Thyroid hormone replacement medication may be permitted if the participant has been on same stable dose for the last 3 months prior to study drug administration. After dosing, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the Investigator or designee. Hormone replacement therapy will also be allowed.
  13. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to dosing and throughout the study.
  14. Donation of blood or significant blood loss within 56 days prior to dosing.
  15. Plasma donation within 7 days prior to dosing.
  16. Has positive results for Coronavirus disease 2019 (COVID-19) testing at screening or check-in.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Low Dose): TAK-951 20 mcg Infusion Over 60 Minutes

    TAK-951 20 microgram (mcg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1.

    Drug: TAK-951 · Drug: TAK-951 Placebo

  • Experimental
    Cohort 2 (High Dose): TAK-951 1 mg Infusion Over 60 Minutes

    TAK-951 1 milligram (mg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.

    Drug: TAK-951 · Drug: TAK-951 Placebo

  • Experimental
    Cohort 3: TAK-951 1 mg Infusion Over 120 Minutes

    TAK-951 1 mg or TAK-951 placebo-matching, infusion, intravenously, over a period of 120 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.

    Drug: TAK-951 · Drug: TAK-951 Placebo

Interventions

  • TAK-951 intravenous infusion.

  • DrugTAK-951 Placebo

    TAK-951 placebo-matching intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Reported One or More Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline up to Day 29

  2. Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values

    Time frame: Baseline up to Day 2

  3. Number of Participants With Clinically Significant Change From Baseline in 12- Lead Electrocardiogram (ECG) Values

    Time frame: Baseline up to Day 2

  4. Number of Participants With Clinically Significant Change From Baseline in Laboratory Values

    Time frame: Baseline up to Day 2

  5. Number of Participants With Clinically Significant Change From Baseline in Physical Examination Values

    Time frame: Baseline up to Day 29

Secondary outcomes

  1. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951

    Time frame: Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose

  2. Ceoi: Plasma Concentration at the End of Infusion for TAK-951

    Time frame: Day 1: at the end of infusion (at 30 hours post-infusion)

  3. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-951

    Time frame: Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose

  4. T1/2z: Terminal Disposition Phase Half-life for TAK-951

    Time frame: Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose

  5. λz: Terminal Disposition Phase Rate Constant for TAK-951

    Time frame: Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose

  6. Number of Participants With Positive Anti-drug Antibodies (ADA) in Serum

    ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.

    Time frame: Baseline up to Day 29

07

Results

Posted Mar 10, 2023

Participant flow

Participants took part in the study at 1 investigative site in the United States from 07 July 2020 to 27 May 2021.

Participant flow — Overall Study
MilestoneCohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
Started4226666
Completed4226656
Not completed0000010
Withdrew: Lost to follow-up0000010

Outcome measures

PrimaryNumber of Participants Who Reported One or More Treatment-emergent Adverse Events (TEAEs)
Time frame:
Baseline up to Day 29
Reported as:
Count of participants · Participants
Number of Participants Who Reported One or More Treatment-emergent Adverse Events (TEAEs)
ParticipantsCohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
Number of Participants Who Reported One or More Treatment-emergent Adverse Events (TEAEs)1013131
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Vital Sign Values
Time frame:
Baseline up to Day 2
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values
ParticipantsCohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values0000000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in 12- Lead Electrocardiogram (ECG) Values
Time frame:
Baseline up to Day 2
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in 12- Lead Electrocardiogram (ECG) Values
ParticipantsCohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
Number of Participants With Clinically Significant Change From Baseline in 12- Lead Electrocardiogram (ECG) Values0000000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Laboratory Values
Time frame:
Baseline up to Day 2
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
ParticipantsCohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values0000000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Physical Examination Values
Time frame:
Baseline up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Values
ParticipantsCohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Values0000000
SecondaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951
Time frame:
Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951
nanogram*hour per milliliter (ng*hr/mL)Cohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-9512.758 ± 25.1110.4 ± 11.0127.7 ± 23.9133.2 ± 9.5
SecondaryCeoi: Plasma Concentration at the End of Infusion for TAK-951
Time frame:
Day 1: at the end of infusion (at 30 hours post-infusion)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Ceoi: Plasma Concentration at the End of Infusion for TAK-951
nanogram per milliliter (ng/mL)Cohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
Ceoi: Plasma Concentration at the End of Infusion for TAK-9510.5203 ± 143.248.95 ± 15.937.03 ± 38.427.06 ± 9.1
SecondaryAUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-951
Time frame:
Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose
Reported as:
Geometric mean · ng*hr/mL
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-951
ng*hr/mLCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-9512.722 ± 25.4110.0 ± 10.8127.2 ± 24.0132.5 ± 9.5
SecondaryT1/2z: Terminal Disposition Phase Half-life for TAK-951
Time frame:
Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose
Reported as:
Mean · hour
T1/2z: Terminal Disposition Phase Half-life for TAK-951
hourCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
T1/2z: Terminal Disposition Phase Half-life for TAK-9514.025 ± 0.71004.670 ± 0.55764.454 ± 0.51244.640 ± 0.3410
Secondaryλz: Terminal Disposition Phase Rate Constant for TAK-951
Time frame:
Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose
Reported as:
Mean · per hour (1/hour)
λz: Terminal Disposition Phase Rate Constant for TAK-951
per hour (1/hour)Cohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
λz: Terminal Disposition Phase Rate Constant for TAK-9510.1781 ± 0.0402650.1501 ± 0.0168790.1574 ± 0.0185430.1500 ± 0.010488
SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADA) in Serum

ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.

Time frame:
Baseline up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies (ADA) in Serum
ParticipantsCohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
Number of Participants With Positive Anti-drug Antibodies (ADA) in Serum0000000

Adverse events

Collected over TEAEs were adverse events that started after the first dose of study drug (Baseline) up to Day 29. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohorts 1 to 2, Treatment P1: Placebo Pooled0/4 (0%)0/4 (0%)1/4 (25%)
Cohort 3, Treatment P2: Placebo0/2 (0%)0/2 (0%)0/2 (0%)
Cohort 4, Treatment P3: Placebo0/2 (0%)0/2 (0%)1/2 (50%)
Cohort 1, Treatment A: TAK-951 20 mcg0/6 (0%)0/6 (0%)3/6 (50%)
Cohort 2, Treatment B: TAK-951 1.0 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Cohort 3, Treatment C: TAK-951 1.0 mg0/6 (0%)0/6 (0%)3/6 (50%)
Cohort 4, Treatment D: TAK-951 1.0 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mg
Medical device site reactionGeneral disorders0/40/21/20/60/60/60/6
Muscle spasmsMusculoskeletal and connective tissue disorders1/40/20/20/60/60/60/6
ArthralgiaMusculoskeletal and connective tissue disorders0/40/20/20/60/61/60/6
Back painMusculoskeletal and connective tissue disorders0/40/20/20/60/60/61/6
DizzinessNervous system disorders0/40/20/21/61/61/60/6
Heart rate increasedInvestigations0/40/20/20/61/60/60/6
Joint swellingMusculoskeletal and connective tissue disorders0/40/20/20/60/61/60/6
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/40/20/21/60/60/60/6
Orthostatic heart rate response increasedInvestigations0/40/20/20/60/61/60/6
PalpitationsCardiac disorders0/40/20/21/60/60/60/6

Baseline characteristics

The safety analysis set consisted of all participants who were enrolled and received the full or partial dose of study drug or placebo.

Age, Categorical
Age, Categorical(Participants)Cohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mgTotal
<=18 years00000000
Between 18 and 65 years422666632
>=65 years00000000
Sex: Female, Male
Sex: Female, Male(Participants)Cohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mgTotal
Female00020103
Male422465629
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mgTotal
Hispanic or Latino00000123
Not Hispanic or Latino422665429
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mgTotal
American Indian or Alaska Native00000000
Asian00010001
Native Hawaiian or Other Pacific Islander00000000
Black or African American11010205
White312454625
More than one race00001001
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(Participants)Cohorts 1 to 2, Treatment P1: Placebo PooledCohort 3, Treatment P2: PlaceboCohort 4, Treatment P3: PlaceboCohort 1, Treatment A: TAK-951 20 mcgCohort 2, Treatment B: TAK-951 1.0 mgCohort 3, Treatment C: TAK-951 1.0 mgCohort 4, Treatment D: TAK-951 1.0 mgTotal
United States422666632
08

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in May 2021, 10 months.

Results were first posted in Mar 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Jul 27, 2020
StartActual
Jul 7, 2020
Primary completionActual
May 16, 2021
CompletionActual
May 27, 2021
Results first posted
Mar 10, 2023
Last update
Mar 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04486950
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 27, 2020
Start date
Jul 7, 2020
Primary completion
May 16, 2021
Completion
May 27, 2021
Results posted
Mar 10, 2023
Last update
Mar 10, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-951

Start the discussion